Peptide Catalog
Browse 251 research compounds across 15 categories including peptides, SARMs, and growth factors. Each entry includes mechanism of action, evidence grade, dosing ranges, half-life, and vendor availability.
Complete research compound database — 251 compounds across 15 categories
Popular Compounds
| Name | Category | Grade | Type | Route | Dose Range | Half-Life | FDA | Uses |
|---|
Related Tools & Resources
Stay Ahead of Peptide Research
Weekly updates on new studies, regulatory changes, protocol guides, and compound analyses. Join 2,000+ researchers.
No spam. Unsubscribe anytime. We respect your privacy.
Frequently Asked Questions
How many peptides are in the database?
The Path to Peptides catalog contains 251 research compounds across 15 categories, including peptides, proteins, small molecules, SARMs, and amino acid derivatives. Each entry includes mechanism of action, evidence grade (A through D), dosing ranges, half-life, route of administration, and FDA approval status. The database is updated regularly as new compounds enter clinical research.
How are peptides categorized?
Compounds are organized into 15 research categories based on primary mechanism of action: GLP-1/Weight Loss, Growth Hormone Secretagogues, Recovery/Tissue Repair, Nootropics/Cognitive, Anti-Aging/Longevity, Immune/Thymic, Sexual Health, Skin/Cosmetic, Metabolic, Antimicrobial, SARMs, Research Chemicals, Hormones, Amino Acids, and Growth Factors. You can filter by category, search by name, or browse alphabetically.
What does each evidence grade mean?
Evidence grades range from A (strong clinical evidence with FDA-approved indications) to D (preliminary or preclinical data only). A- indicates strong clinical data without full FDA approval for the specific use. B+ and B indicate moderate clinical evidence from human trials. B- indicates limited clinical data. C+ indicates promising preclinical research. C indicates early-stage or animal-only research. All grades are assigned based on peer-reviewed literature indexed in PubMed.